Medscape is available in 5 Language Editions – Choose your Edition here.


Complex Regional Pain Syndromes

  • Author: Anthony H Wheeler, MD; Chief Editor: Stephen A Berman, MD, PhD, MBA  more...
Updated: Jul 15, 2016


In 1994, a consensus group of pain medicine experts gathered by the International Association for the Study of Pain (IASP) agreed on diagnostic criteria for reflex sympathetic dystrophy (RSD) and causalgia, and renamed them complex regional pain syndrome (CRPS) types I and II, respectively. These designations were determined by the type of inciting event, rather than by any differences in clinical presentation or pathophysiology. Many experts felt that the IASP diagnostic criteria were ambiguous; however, these criteria were developed as just a starting point, and the IASP fully intended to validate them through clinical research studies.{ref1-INVALID REFERENCE}[1]

CRPS type I requirements feature causation by an initiating noxious event, such as a crush or soft tissue injury; or by immobilization, such as a tight cast or frozen shoulder. CRPS type II is characterized by the presence of a defined nerve injury. Both types demonstrate continuing pain, allodynia, or hyperalgesia that is usually disproportionate to the inciting event. At some point during the syndrome's development, both show evidence of edema, changes in skin blood flow revealed by color changes and skin temperature changes greater than 1.1°C from the homologous body part, or abnormal sudomotor activity in the painful region. Both types require the exclusion of any other condition that might account for the degree of pain and dysfunction seen.{ref1-INVALID REFERENCE}[2]

The 1994 IASP criteria have proven to be extremely sensitive (ie, they rarely miss a true case of CRPS). However, since their inception, the 1994 taxonomy has been criticized by experts on clinical criteria validation and specialists in pain medicine on the grounds that the criteria are insufficiently specific (ie, use of the criteria results in overdiagnosis of CRPS). A small single center validation study demonstrated empirically that the 1994 CRPS criteria did indeed cause overdiagnosis of the syndrome.[2]

In response to such concerns, investigators used factor analysis to categorize 123 patients with CRPS into 4 statistically distinct subgroups.[3] This resulted in modified diagnostic criteria felt to be valuable for further validation studies.[3, 4]

In 2003, a closed workshop was held in Budapest, Hungary to study and resolve this matter. Experts in CRPS published the results of this workshop in a 2007 review article[5] showing that the modified criteria, mentioned above, produced better discrimination between CRPS and non-CRPS neuropathic pain, yielding better diagnostic accuracy than the original unmodified criteria.[5]

The study results indicated that when 2 of 4 sign categories were present and 3 of 4 symptom categories were present, the resultant sensitivity was 0.85 and the specificity was 0.69 for a clinical diagnosis of CRPS. This appeared to be a good compromise between identifying as many patients as possible in the clinical context and substantially reducing the high level of false-positive diagnoses associated with the 1994 IASP criteria. However, a higher specificity is required to meet research criteria, so the committee recommended that 2 of the 4 sign categories and all 4 symptom categories must be positive for the diagnosis to be made in a research setting, resulting in a sensitivity of 0.70 and specificity of 0.94.

Due to the combination of increased specificity and reduced sensitivity, about 15% of patients previously diagnosed with CRPS were considered "without a diagnosis." Therefore, a third diagnostic subtype, complex regional pain syndrome not otherwise specified (CRPS-NOS), was recommended to categorize those patients.[6] These new IASP diagnostic criteria have been submitted to the medical committee for Classification of Chronic Pain of the IASP for future revision of formal taxonomy and diagnostic criteria. 

The criteria are given here in hopes that higher specificity for the identification of CRPS will enhance research into the pathoetiology of this disorder without creating a reduced, or even harmful, rate of clinical diagnosis that could deny affected patients access to treatment. In addition, these criteria may result in more cost-effective approaches for the management of this disorder.[5, 7, 6]  These criteria, as listed below, are given in the most current version of the IASP's Complex regional pain syndrome: practical diagnostic and treatment guidelines (4th edition)[8]  where they are described as "state of the art" diagnostic criteria and "practical" guidelines. 

IASP-proposed revised CRPS clinical diagnostic criteria

A clinical diagnosis of CRPS can be made when the following criteria are met:

  • Continuing pain that is disproportionate to any inciting event
  • At least 1 symptom reported in at least 3 of the following categories:
    • Sensory: Hyperesthesia or allodynia
    • Vasomotor: Temperature asymmetry, skin color changes, skin color asymmetry
    • Sudomotor/edema: Edema, sweating changes, or sweating asymmetry
    • Motor/trophic: Decreased range of motion, motor dysfunction (eg, weakness, tremor, dystonia), or trophic changes (eg, hair, nail, skin)
  • At least 1 sign at time of evaluation in at least 2 of the following categories:
    • Sensory: Evidence of hyperalgesia (to pinprick), allodynia (to light touch, temperature sensation, deep somatic pressure, or joint movement)
    • Vasomotor: Evidence of temperature asymmetry (>1°C), skin color changes or asymmetry
    • Sudomotor/edema: Evidence of edema, sweating changes, or sweating asymmetry
    • Motor/trophic: Evidence of decreased range of motion, motor dysfunction (eg, weakness, tremor, dystonia), or trophic changes (eg, hair, nail, skin)
  • No other diagnosis better explaining the signs and symptoms

In addition, a slightly modified version of the above listing is used for CRPS research (as opposed to clinical) criteria. For these rules one must have the CRPS characteristics present in all four of the symptom categories and in at least two out of the four sign categories.



Hypothetical mechanisms

In most cases, experts believe that CRPS develops when persistent noxious stimuli from an injured body region leads to peripheral and central sensitization, whereby primary afferent nociceptive mechanisms demonstrate abnormally heightened sensation, including spontaneous pain and hyperalgesia. Allodynia and hyperalgesia occur when central nervous system (CNS) somatosensory processing misinterprets normal nonpainful mechanical stimuli, such as light touching of the skin, as painful. Therefore, skin in the injured area becomes more sensitive to all stimuli, even nonpainful stimuli. In addition, the sensitization can extend beyond the originally injured area, thus enlarging the region of aberrant pain perception.

A similar impairment of CNS processing leads to motor aberrancies, such as weakness or tremor in the affected area. The peripheral and central sensitization associated with impaired CNS processing is linked to proposed disturbances within the sympathetic nervous system (SNS) that lead to sympathetic hyperactivity adversely affecting the injured area. Studies suggest that an augmented inflammatory response coupled with impaired healing further contribute to the refractory nature of malevolent CRPS.[9, 1, 10, 11, 12, 13]

Peripheral and central sensitization

Mechanical, thermal, and chemical stimuli activate peripheral nociceptors that transmit pain messages through lightly myelinated A-delta fibers and unmyelinated C fibers projecting to Rexed layers I, II, and V in the spinal cord. This process leads to the release of excitatory amino acids, such as glutamine and asparagine, which then act upon N -methyl-D -aspartic acid (NMDA) receptors, causing the release of substance P (SP). SP then lowers the threshold for synaptic excitability in normally silent second-order interspinal synapses.[9, 1, 10, 11, 12]

Peripheral sensitization occurs when persistent or repetitive noxious stimulation of high-threshold, polymodal C fibers results in enhanced sensitivity, lower stimulus thresholds, and the prolonged, enhanced activation of dorsal horn cells, especially those with glutamate receptors. In addition to SP, algogenic substances that are typically involved in tissue damage and capable of inducing transduction centripetally include potassium, serotonin, bradykinin, histamine, prostaglandins, and leukotrienes. Neuropeptides, such as SP and calcitonin gene-related peptide (CGRP), are also transported to the endings of nociceptive afferents where they can instigate ortho- and retrograde actions including, but not limited to, neurogenic inflammation, which can incite a host of additional hostile algogenic mechanisms.

Chronic CNS sensitization is engendered through afferent processing by second-order nociceptor-specific neurons and wide-dynamic-range (WDR) neurons in the spinal cord. WDR neurons contribute more to sensitivity than nociceptor-specific neurons, because both nociceptive and non-nociceptive afferents converge to synapse on a single WDR neuron, and WDR neurons respond with equal intensity regardless of whether the neural signal is noxious (hyperalgesia) or not.

Hyperalgesia and allodynia initially develop at the injury site. However, after CNS sensitization occurs through WDR neural activity, the area of pain expands beyond the initial region of tissue pathology. The peripheral changes described eventually cause an injury environment, where primary afferents, including nociceptors, demonstrate an increased sensitivity to circulating or experimentally injected subcutaneous norepinephrine.[14, 1, 10, 11, 12, 15, 16, 17, 18, 19, 20]

In addition to functional CNS sensitization, recent investigations have explored the possibility that the brain of those with CRPS may differ structurally from brains of those without CRPS. Studies of small numbers of patients from various authors suggest that patients with CRPS may have, for example, diminished thickness of the prefrontal cortex[21]  or diminished gray matter volume in certain regions related to pain perception but greater gray matter volume in other regions.[22]  Another group found evidence that the choroid plexus is enlarged in CRPS.[23]   More recently, van Velzen et al. studied 19 of their own patients and conducted a review of the existing literature. They failed to find any specific differences in the structure of function of the brain in CRPS patients and they also concluded that prior results in the literature were inconsistent with regard to the location and amount of the supposed changes as well as in the direction of the changes.[24] At present, the idea that structural brain changes may underly CRPS remains intriguing but inconclusive.

Sympathetically maintained pain (SMP)

For decades, CRPS was thought to be caused by SNS hyperactivity, and the pain experienced by those who suffer from CRPS was believed to be SMP. SNS involvement in CRPS is supported clinically by the presence of abnormal patterns in skin temperature, skin color, and sweating in the affected extremities. Surgical and chemical sympathectomy can relieve pain in some cases. However, under normal physiological circumstances, there is no interaction between the sympathetic and peripheral afferent nociceptive neurons.[14, 1, 25, 26, 27] Furthermore, multiple discrepancies undermine the possibility of SNS involvement. These discrepancies include the following: (1) plasma catecholamine concentrations are lower in CRPS-affected limbs[28, 29] , (2) most CRPS patients do not obtain significant or lasting pain relief from sympathetic blocks[30, 31] , and (3) skin temperature does not correlate with the activity of sympathetic vasoconstrictor neurons.[32]

To explain these incongruities, the pathophysiology of SMP was hypothesized to involve an abnormal coupling between sympathetic efferent and nociceptive afferent neurons.[33] Two possible conditions may lead to pathological coupling: interactions between sympathetic efferents and intact or regenerating peripheral nociceptive C-fiber neurons, or between sympathetic vasoconstrictor neurons and afferent somata within the dorsal root ganglion (DRG).[34]

This coupling is mediated by norepinephrine, which is released from newly expressed sympathetic terminals and adrenoreceptors onto afferent nociceptive neurons. Indeed, increased mRNA for alpha-2-adrenoreceptors has been demonstrated in DRG neurons following a nerve injury.[35] Therefore, an increased number of targeted and functionally upregulated adrenoreceptors on lesioned nociceptive afferents, which has been demonstrated, would explain how reduced SNS activity in CRPS is capable of maintaining pain.[26, 1]

Evidence suggests that early autonomic symptoms and signs of CRPS are indicative of CNS dysfunction.[36] Wasner et al suggest that warmth of the affected extremity in the early stages of CRPS I is caused by the functional inhibition of central cutaneous vasoconstrictor activity, leading to cutaneous vasodilation.[27] However, over time, this inhibition may lead to adrenergic hypersensitivity from peripheral denervation and/or sympathetic denervation.

Thus, in CRPS I, the early inhibition of central cutaneous vasoconstrictor activity leads to vasodilation in the denervated area causing it to feel warm. The later increased sensitivity to circulating catecholamines due to upregulation of cutaneous adrenoreceptors causes vasoconstriction and coolness. Interestingly, studies of direct nerve injuries (CRPS II) show the same results. Initially, vasodilation is present within the denervated area, causing the skin adjacent and on the same side to become abnormally warm at first and then change to a chronically cold status. Other mechanisms include an increased density of cutaneous α-adrenoreceptors and a pathological upregulation of α-adrenergic receptors.[14, 1, 31, 25, 33, 34, 35, 36, 27]

Based on recent clinical studies, patients with neuropathic pain presenting with similar clinical signs and symptoms can be clearly divided into 2 groups by the positive and negative effects of selective sympathetic blockade, selective activation of sympathetic activity, and antagonism of α-adrenergic receptor mechanisms.[37] Pain relieved by sympatholytic procedures is considered to be SMP. SMP is now defined as a symptom or underlying mechanism in a subset of patients with neuropathic disorders. CRPS is one such neuropathic disorder. However, SMP is not a clinical entity per se. Nor is it a sine qua non for CRPS as was previously believed. Thus, the positive effect of sympathetic blockade is not essential for the diagnosis of CRPS. On the other hand, the only way to differentiate between SMP and sympathetically independent pain (SIP) is to test the efficacy of a correctly applied sympatholytic intervention.[38]

Sensory and motor dysfunction

In both types of CRPS, peripheral and central sensitization explain the pathophysiology of spontaneous pain and hyperalgesia.[39] Clinical findings in patients consistently show sensory impairments that spread beyond the injured territory, and spontaneous pain that often engulfs a quadrant or hemisensory region. These abnormal patterns are due to altered central afferent processing and have been delineated with functional imaging studies.[40, 41, 42]

Likewise, the evidence to date supports the presence of similar mechanisms involving abnormalities of CNS motor processing (rather than pain, edema, disuse, trophic changes, or nerve injury) that are responsible for causing impairments of muscle strength in the involved distal extremity. Kinematic analysis studies suggest that motor deficits are probably due to impaired integration of visual and sensory afferent input within the parietal cortex.[43] Also, an increased amplitude of physiological tremor due to CNS mechanisms is common, occurring in about 50% of patients under observation.[44]

Aberrant healing and exaggerated inflammation

After tissue injury, the body's response is programmed to promote healing, with the goal of regaining full use of the injured body part. Some experts have hypothesized that CRPS is caused by an aberrant healing response that includes exaggerated and persistent inflammation and guarding.

At the site of injury, peripheral C-fiber nociceptors transmit pain messages that cause ortho- and retrograde release of SP and CGRP into the damaged tissues, resulting in vasodilation, extravasation of pronociceptive mediators, reactivation and further sensitization of C-fiber afferents, and increased tissue comorbidity in the injured area.[14, 10] These neuropeptides prompt the physical signs of inflammation, including redness, warmth, and swelling, that are also commonly present in early CRPS. Also, algogenic substances are released, which increase nociception and initiate the process of peripheral sensitization previously discussed. Skin sensitivity and tenderness spread into adjacent regions, which are thought to be caused by secondary hyperalgesia from CNS alterations that are consistent with the described sensitization process.

Protective disuse

Decreased use of an injured body part would appear to be a normal postinjury reaction. After injury, the organism protects and guards the injured body part to optimize healing and prevent reinjury. A normally healing organism gradually increases its use of the injured region, which aids in recovery and reintegration of the body part into the organism’s normal sense of self. However, excessive protection and guarding, such as casting or splinting, is commonly promoted by care providers, increasing the patient’s disuse of the extremity and promoting fear-avoidance, which may progress into a neurological neglect-like syndrome.

This phenomenon has been postulated as a cause in some patients with CRPS.[44] Many of the symptoms and signs of CRPS are consistent with those that would naturally develop from lack of use. For example, an unused dependent limb eventually develops swelling (dependent edema), coolness (decreased blood flow), and trophic changes (decreased blood flow).[14, 1, 45]




United States

A population-based study by Sandroni et al showed an incidence of approximately 5.5 per 100,000 person-years at risk and a prevalence of about 21 per 100,000 for CRPS type I.[46] The same study showed an incidence of 0.8 per 100,000 and a prevalence of about 4 per 100,000 for CRPS type II.[46, 14] Therefore, the incidence of CRPS type I is higher than that of CRPS type II.[46, 14] The reported incidence of CRPS type I is 1-2% after various fractures[14] , while that of CRPS type II approximates 1-5% after peripheral nerve injury[14, 47] . The incidence of CRPS is 12% after a brain injury[48] and 5% after a myocardial infarction[49] .


A study from the Netherlands showed a total incidence of CRPS of approximately four times higher than the incidence rate observed in the only other population-based study, performed in Olmsted County, USA.[50] The estimated overall incidence rate of CRPS was 26.2 per 100,000 person years with females affected at least three times more often than males. The highest incidence occurred in females aged 61-70 years. The upper extremity was affected more frequently than the lower extremity and a fracture was the most common precipitating event (44%).[50]


Despite treatment, many patients are left with varying degrees of chronic pain, trophic changes, and disability. Pain is the most important factor leading to disability. Some have suggested that the aggressive treatment of pain in an acute setting could reduce the incidence of CRPS type I; however, further studies are needed to support this contention. Remissions followed by relapses have also been described. The frequency of the HLA-DQ1 antigen appears to be higher in patients with CRPS than in controls, and HLA-DR13 is associated with progression towards multifocal or generalized dystonia.[51, 52] Recently, a new HLA I locus was detected that may predict the spontaneous onset of CRPS.[53]

Race-, sex-, and age-related demographics

CRPS affects all races; no differences in incidence or prevalence have been observed.

Females experience CRPS more commonly than males do by a ratio that varies from 2:1 to 4:1.[14, 54, 46, 55, 56, 4, 57]

CRPS is distributed across age groups, but reaches its peak incidence between 37 and 50 years.[14, 54, 46, 55, 56, 4, 57] CRPS has an increased incidence in adolescents, compared with children, with females affected more frequently at a ratio of 4:1 and increased occurrence in the lower extremities rather than the upper by a ratio of 5.3:1. The mean age of onset is 12.5 years in a cohort of 396 children. The highest incidence of the disease appears to be in adults aged 40-49 years. CRPS appears frequently in almost every age group except children. CRPS type I has been seen in children, but the incidence is much lower than in adults.

Contributor Information and Disclosures

Anthony H Wheeler, MD Pain and Orthopedic Neurology, Charlotte, North Carolina

Anthony H Wheeler, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pain Medicine, North American Spine Society, North Carolina Medical Society

Disclosure: Received salary from Allergan, Inc. for speaking and teaching; Received none from Gralise for consulting.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Glenn Lopate, MD Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, Phi Beta Kappa

Disclosure: Nothing to disclose.

Chief Editor

Stephen A Berman, MD, PhD, MBA Professor of Neurology, University of Central Florida College of Medicine

Stephen A Berman, MD, PhD, MBA is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, Phi Beta Kappa

Disclosure: Nothing to disclose.

Additional Contributors

Jorge E Mendizabal, MD Consulting Staff, Corpus Christi Neurology

Jorge E Mendizabal, MD is a member of the following medical societies: American Academy of Neurology, National Stroke Association, American Headache Society, Stroke Council of the American Heart Association

Disclosure: Nothing to disclose.

  1. Galer BS, Schwartz L, Allen RJ. Loeser JD, Butler SH, Chapman RC, Turk DC,(eds). Complex regional pain syndromes-- Type I: reflex sympathetic dystrophy, and type II: causalgia, in: Bonica’s management of pain. Philadelphia: Lippincott Williams & Wilkins; 2001. 388- 411.

  2. Galer BS, Jensen M. Neglect-like symptoms in complex regional pain syndrome: results of a self-administered survey. J Pain Symptom Manage. 1999 Sep. 18(3):213-7. [Medline].

  3. Harden RN, Bruehl S, Galer BS, et al. Complex regional pain syndrome: are the IASP diagnostic criteria valid and sufficiently comprehensive?. Pain. 1999 Nov. 83(2):211-9. [Medline].

  4. Bruehl S, Harden RN, Galer BS, et al. External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria. International Association for the Study of Pain. Pain. 1999 May. 81(1-2):147-54. [Medline].

  5. Harden RN, Bruehl S, Stanton-Hicks M, Wilson PR. Proposed new diagnostic criteria for complex regional pain syndrome. Pain Medicine. 2007. 6(4):326 31.

  6. Wilson PR, Stanton-Hicks, M, Harden RN. CRPS. Current Diagnosis and Therapy. Progress in Pain Research and Management Series. IASP Press: Seattle, WA; 2005. Vol. 32:

  7. Bruehl S, Harden RN, Galer BS, Saltz S, Backonja M, Stanton-Hicks M. Complex regional pain syndrome: are there distinct subtypes and sequential stages of the syndrome?. Pain. 2002 Jan. 95(1-2):119-24. [Medline].

  8. Harden RN, Oaklander AL, Burton AW, Perez RS, Richardson K, Swan M, et al. Complex regional pain syndrome: practical diagnostic and treatment guidelines, 4th edition. Pain Med. 2013 Feb. 14 (2):180-229. [Medline].

  9. Baron R, Levine JD, Fields HL. Causalgia and reflex sympathetic dystrophy: does the sympathetic nervous system contribute to the generation of pain?. Muscle Nerve. 1999 Jun. 22(6):678-95. [Medline].

  10. Giordano J, Boswell MV. Neurobiology of nociceptive and anti-nociceptive systems. Manchikanti L, Singh V(eds). Interventional techniques in chronic spinal pain. Paducah, Kentucky: ASSIP publishing; 2007. 17-32.

  11. Kawakami, Chatenia K, Weinstein JN. AH, Schofferman JA (ed.). Anatomy, biochemistry, and physiology of low back pain, in White Spine Care: diagnosis and conservative treatment. St. Louis: Mosby Press; 1995. pp 84-103.

  12. Wheeler AH, Murrey DB. Spinal pain: pathogenesis, evolutionary mechanisms and management. Pappagallo M, ed. The Neurologic Basis of Pain. New York: McGraw-Hill; 2003. 421-52.

  13. Rockett M. Diagnosis, mechanisms and treatment of complex regional pain syndrome. Curr Opin Anaesthesiol. 2014 Oct. 27(5):494-500. [Medline].

  14. Baron R, Binder A. Pappagallo M (ed). complex regional pain syndromes, in The neurological basis of pain. New York: McGraw-Hill; 2005:. 359-378.

  15. Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc. 1999 Apr. 74(4):385-98. [Medline].

  16. Carlton SM, Zhou S, Coggeshall RE. Evidence for the interaction of glutamate and NK1 receptors in the periphery. Brain Res. 1998 Apr 20. 790(1-2):160-9. [Medline].

  17. Mendell LM, Wall PD. Responses of Single Dorsal Cord Cells to Peripheral Cutaneous Unmyelinated Fibres. Nature. 1965 Apr 3. 206:97-9. [Medline].

  18. Fields HL. Pain. New York: McGraw-Hill; 1987.

  19. Schofferman JA. 23-6. White AH, Schofferman JA (eds.). Applied neurophysiology of pain, in Spine Care: diagnosis and conservative treatment. St Louis: Mosby Press; 1995.

  20. Russell IJ. Neurochemical pathogenesis of fibromyalgia syndrome. J Musculoskeletal Pain. 1996. 4:61-92.

  21. Lee DH, Lee KJ, Cho KI, Noh EC, Jang JH, Kim YC, et al. Brain alterations and neurocognitive dysfunction in patients with complex regional pain syndrome. J Pain. 2015 Jun. 16 (6):580-6. [Medline].

  22. Pleger B, Draganski B, Schwenkreis P, Lenz M, Nicolas V, Maier C, et al. Complex regional pain syndrome type I affects brain structure in prefrontal and motor cortex. PLoS One. 2014. 9(1):e85372. [Medline]. [Full Text].

  23. Zhou G, Hotta J, Lehtinen MK, Forss N, Hari R. Enlargement of choroid plexus in complex regional pain syndrome. Sci Rep. 2015 Sep 21. 5:14329. [Medline].

  24. van Velzen GA, Rombouts SA, van Buchem MA, Marinus J, van Hilten JJ. Is the brain of complex regional pain syndrome patients truly different?. Eur J Pain. 2016 May 10. [Medline].

  25. Janig W, Koltzendbrg M. Bond MR, Charlton EJ, Woolf CJ (eds). sympathetic reflex activity and neuro- factor transmission change after chronic nerve lesions in Proceedings of the VIth world Congress on pain. Amsterdam: Elsevier Science; 1991. 365-371.

  26. Baron R, Wasner G, Borgestedt R, et al. Effects of sympathetic activity on capsaicin-evoked pain, hyperalgesia and vasodilation Neurology. 1999. 52:923-932.

  27. Wasner G, Schattschneider J, Heckmann K, Maier C, Baron R. Vascular abnormalities in reflex sympathetic dystrophy (CRPS I): mechanisms and diagnostic value. Brain. 2001 Mar. 124:587-99. [Medline].

  28. Drummond PD, Finch PM, Gibbins I. Innervation of hyperalgesic skin in patients with complex regional pain syndrome. Clin J Pain. 1996 Sep. 12(3):222-31. [Medline].

  29. Harden RN, Duc TA, Williams TR, Coley D, Cate JC, Gracely RH. Norepinephrine and epinephrine levels in affected versus unaffected limbs in sympathetically maintained pain. Clin J Pain. 1994 Dec. 10(4):324-30. [Medline].

  30. Treede RD, Davis KD, Campbell JN, Raja SN. The plasticity of cutaneous hyperalgesia during sympathetic ganglion blockade in patients with neuropathic pain. Brain. 1992 Apr. 115 (Pt 2):607-21. [Medline].

  31. Chelimsky TC, Low PA, Naessens JM, Wilson PR, Amadio PC, O'Brien PC. Value of autonomic testing in reflex sympathetic dystrophy. Mayo Clin Proc. 1995 Nov. 70(11):1029-40. [Medline].

  32. Jänig W. Experimental approach to reflex sympathetic dystrophy and related syndromes. Pain. 1991 Sep. 46(3):241-5. [Medline].

  33. Jänig W, Levine JD, Michaelis M. Interactions of sympathetic and primary afferent neurons following nerve injury and tissue trauma. Prog Brain Res. 1996. 113:161-84. [Medline].

  34. McLachlan EM, Jänig W, Devor M, Michaelis M. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature. 1993 Jun 10. 363(6429):543-6. [Medline].

  35. Shi TS, Winzer-Serhan U, Leslie F, Hokfelt T. Distribution and regulation of alpha(2)-adrenoceptors in rat dorsal root ganglia. Pain. 2000 Feb. 84(2-3):319-30. [Medline].

  36. Janig W, Baron R. Complex regional pain syndrome is a disease of the central nervous system. Clin Auton Res. 2002 Jun. 12(3):150-64. [Medline].

  37. Raja AN, Treede RD, Davis KD, et al. Systemic alpha-adrenergic blockade with phentolamine: a diagnostic test for sympathetically maintained pain. Anesthesiology. 1991. 74:691-698.

  38. Stanton-Hicks M, Janig W, Hassenbusch S, Haddox JD, Boas R, Wilson P. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain. 1995 Oct. 63(1):127-33. [Medline].

  39. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999 Jun 5. 353(9168):1959-64. [Medline].

  40. Rommel O, Gehling M, Dertwinkel R, et al. Hemisensory impairment in patients with complex regional pain syndrome. Pain. 1999 Mar. 80(1-2):95-101. [Medline].

  41. Juottonen K, Gockel M, Silen T, Hurri H, Hari R, Forss N. Altered central sensorimotor processing in patients with complex regional pain syndrome. Pain. 2002 Aug. 98(3):315-23. [Medline].

  42. Fukumoto M, Ushida T, Zinchuk VS, Yamamoto H, Yoshida S. Contralateral thalamic perfusion in patients with reflex sympathetic dystrophy syndrome. Lancet. 1999 Nov 20. 354(9192):1790-1. [Medline].

  43. Schattschneider J, Wenzelburger R, Deuschl G, et al. Harden RN, Baron R, Janig W (eds). Kinematic analysis of the upper extremity in CRPS, in Progress in pain research and management: complex regional pain syndrome. IASP Press: Seattle; 1999. 119-128.

  44. Deuschl, Blumberg S, Jensen M. Tremor in reflex sympathetic dystrophy. Arch Neurol. 1999. 48:1247-1252.

  45. Galer BS, Butler S, Jensen MP. Case reports and hypothesis: a neglect-like syndrome may be responsible for the motor disturbance in reflex sympathetic dystrophy (Complex Regional Pain Syndrome-1). J Pain Symptom Manage. 1995 Jul. 10(5):385-91. [Medline].

  46. Sandroni P, Benrud-Larson LM, McClelland RL, Low PA. Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. Pain. 2003 May. 103(1-2):199-207. [Medline].

  47. Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet. 1993 Oct 23. 342(8878):1012-6. [Medline].

  48. Gellman H, Keenan MA, Stone L, Hardy SE, Waters RL, Stewart C. Reflex sympathetic dystrophy in brain-injured patients. Pain. 1992 Dec. 51(3):307-11. [Medline].

  49. Rosen PS, Graham W. The shoulder-hand syndrome: historical review with observations on seventy-three patients. Can Med Assoc J. 1957 Jul 15. 77(2):86-91. [Medline].

  50. de Mos M, de Bruijn AG, Huygen FJ, Dieleman JP, Stricker BH, Sturkenboom MC. The incidence of complex regional pain syndrome: a population-based study. Pain. 2007 May. 129(1-2):12-20. [Medline].

  51. Kemler MA, van de Vusse AC, van den Berg-Loonen EM, Barendse GA, van Kleef M, Weber WE. HLA-DQ1 associated with reflex sympathetic dystrophy. Neurology. 1999 Oct 12. 53(6):1350-1. [Medline].

  52. Van Hilten JJ, Van De Beek WJ, Roep BO. Multifocal or generalized tonic dystonia complex regional pain syndrome: a distinct clinical in entity associated with HLA-DR13. Ann Neurol. 2000. 48:113-116.

  53. Van De Beek WJ, Roep BO, Van Der Slik AR, et al. Susceptibility loci for complex regional pain syndrome. Neurology. 2003. 103:93-97.

  54. Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet. 1993 Oct 23. 342(8878):1012-6. [Medline].

  55. Allen G, Galer BS, Schwartz L. Epidemiology of complex regional pain syndrome: a retrospective chart review of 134 patients. Pain. 1999 Apr. 80(3):539-44. [Medline].

  56. Low P, Wilson PR, Sandroni P, et al. Janig W, Stanton-Hicks M (eds). Clinical characteristics of patients with reflex sympathetic dystrophy (sympathically maintained pain) in the United States, in Progress in Pain Research and Management: Reflex Sympathetic Dystrophy: A Reappraisal. Seattle: IASP Press; 1996. 49-66.

  57. Baron R, Blimberg, H, Janig, W. Janig W, Stanton-Hiocks M (eds). Clinical characteristics of patients with complex regional pain syndrome in Germany, with special emphasis on vasomotor function, in Progress in Pain Research and Management: Reflex Sympathetic Dystrophy: A Reappraisal. Seattle: IASP Press; 1996. 25-48.

  58. Stengel M, Binder A, Baron R. Update on the diagnosis and management of complex regional pain syndrome. Adv Pain Manage. 2007. (3):96-104.

  59. Todorovic-Tirnanic M, Obradovic V, Han R, Goldner B, Stankovic D, Sekulic D. Diagnostic approach to reflex sympathetic dystrophy after fracture: radiography or bone scintigraphy?. Eur J Nucl Med. 1995 Oct. 22(10):1187-93. [Medline].

  60. Kozin F, Soin JS, Ryan LM, Carrera GF, Wortmann RL. Bone scintigraphy in the reflex sympathetic dystrophy syndrome. Radiology. 1981 Feb. 138(2):437-43. [Medline].

  61. Zyluk A. The usefulness of quantitative evaluation of three-phase scintigraphy in the diagnosis of post-traumatic reflex sympathetic dystrophy. J Hand Surg (Br). 1999. 24:16-21.

  62. Wilder RT. Ref lex sympathetic dystrophy in children and adolescents: differences from adults. Janig W, Stanton-Hicks MD, editors. Reflex Sympathetic Dystrophy: A Reappraisal. Progress in Pain Research and Management Series. Seattle, WA: IASP Press; 1996. Vol.6: 67-78.

  63. Graif M, Schweitzer ME, Marks B, Matteucci T, Mandel S. Synovial effusion in reflex sympathetic dystrophy: an additional sign for diagnosis and staging. Skeletal Radiol. 1998 May. 27(5):262-5. [Medline].

  64. Rommel O, Malin JP, Zenz M, Janig W. Quantitative sensory testing, neurophysiological and psychological examination in patients with complex regional pain syndrome and hemisensory deficits. Pain. 2001 Sep. 93(3):279-93. [Medline].

  65. Price DD, Long S, Huitt C. Sensory testing of pathophysiological mechanisms of pain in patients with reflex sympathetic dystrophy. Pain. 1992 May. 49(2):163-73. [Medline].

  66. Gulevich SJ, Conwell TD, Lane J, Lockwood B, Schwettmann RS, Rosenberg N. Stress infrared telethermography is useful in the diagnosis of complex regional pain syndrome, type I (formerly reflex sympathetic dystrophy). Clin J Pain. 1997 Mar. 13(1):50-9. [Medline].

  67. Birklein F, Riedl B, Neundorfer B et al. Sympathetic vasoconstrictor reflex pattern in patients with complex regional pain syndrome. Pain. 1998. 75:93-100.

  68. Huygen FJ, De Bruijn AG, De Bruin MT et al. Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm. 2002. 11:47-51.

  69. Huygen FJ, Ramdhani N, van Toorenenbergen A, Klein J, Zijlstra FJ. Mast cells are involved in inflammatory reactions during Complex Regional Pain Syndrome type 1. Immunol Lett. 2004 Feb 15. 91(2-3):147-54. [Medline].

  70. Groeneweg JG, Huygen FJ, Heijmans-Antonissen C et al. Increased endothelin-1 and diminished nitric oxide levels in blister fluids of patients with intermediate cold type complex regional pain syndrome type 1. BMC Musculoskelet Disord. 2006. 7:91.

  71. Munnikes RJ, Muis C, Boersma M et al. Intermediate stage complex regional pain syndrome type 1 is unrelated to proinfiamniatory cytokines. Mediators Inflamm. 2005. 14:366-72.

  72. Oaklander AL, Rissmiller JG, Gelman LB et al. Evidence of local small-fiber axonal degeneration in complex regional pain syndrome-1 (reflex sympathetic dystrophy). Pain. 2006. 120:235-43.

  73. Janig W, Baron R. Is CRPS I a neuropathic pain syndrome? Pain. 2006. 120:227-9.

  74. Forouzanfar T, Köke AJ, van Kleef M, Weber WE. Treatment of complex regional pain syndrome type I. Eur J Pain. 2002. 6(2):105-22. [Medline].

  75. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain. 1997 Nov. 73(2):123-39. [Medline].

  76. Perez RS, Kwakkel G, Zuurmond WW, de Lange JJ. Treatment of reflex sympathetic dystrophy (CRPS type 1): a research synthesis of 21 randomized clinical trials. J Pain Symptom Manage. 2001 Jun. 21(6):511-26. [Medline].

  77. Kozin, F. McCarty, Sims, J, et al. The reflex sympathetic dystrophy syndrome: I. Clinical and histological studies: evidence for bilaterality, response to corticosteroids and articular involvement. Jam J Med. 1976. 60:321-331.

  78. Christensen K, Jensen EM, Noer I. The reflex dystrophy syndrome response to treatment with systemic corticosteroids. Acta Chir Scand. 1982. 148(8):653-5. [Medline].

  79. Braus DF, Krauss JK, Strobel J. The shoulder-hand syndrome after stroke: a prospective clinical trial. Ann Neurol. 1994 Nov. 36(5):728-33. [Medline].

  80. Gobelet C, Waldburger M, Meier JL. The effect of adding calcitonin to physical treatment on reflex sympathetic dystrophy. Pain. 1992 Feb. 48(2):171-5. [Medline].

  81. Adami S, Fossaluzza V, Gatti D, Fracassi E, Braga V. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis. 1997 Mar. 56(3):201-4. [Medline].

  82. Varenna M, Zucchi F, Ghiringhelli D, Binelli L, Bevilacqua M, Bettica P. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol. 2000 Jun. 27(6):1477-83. [Medline].

  83. Manicourt DH, Brasseur JP, Boutsen Y, Depreseux G, Devogelaer JP. Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. Arthritis Rheum. 2004 Nov. 50(11):3690-7. [Medline].

  84. Galer BS. Topical lidocaine releives perpheral neuropathic pain (abst). American Academy of Neurology Annual Meeting . 1995.

  85. Galer BS, Miller KV, Rowbotham MC. Response to intravenous lidocaine infusion differs based on clinical diagnosis and site of nervous system injury. Neurology. 1993 Jun. 43(6):1233-5. [Medline].

  86. Glazer S, Portenoy RK. Systemic local anesthetics in pain control. J Pain Symptom Manage. 1991 Jan. 6(1):30-9. [Medline].

  87. Devers A, Galer BS. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open label pilot study. Clin J Pain. 2000 (in press).

  88. van Hilten BJ, van de Beek WJ, Hoff JI, Voormolen JH, Delhaas EM. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med. 2000 Aug 31. 343(9):625-30. [Medline].

  89. Mellick GA, Mellicy LB, Mellick LB. Gabapentin in the management of reflex sympathetic dystrophy. J Pain Symptom Manage. 1995 May. 10(4):265-6. [Medline].

  90. Serpell MG. Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndromes: a randomised. double-blind, placebo-controlled trial. Pain. 2002. 99:557-66.

  91. van de Vusse AC, Goossens VJ, Kemler MA, Weber WE. Screening of patients with complex regional pain syndrome for antecedent infections. Clin J Pain. 2001 Jun. 17(2):110-4. [Medline].

  92. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998 Dec 2. 280(21):1837-42. [Medline].

  93. Scadding JW, Wall PD, Parry CB, Brooks DM. Clinical trial of propranolol in post-traumatic neuralgia. Pain. 1982 Nov. 14(3):283-92. [Medline].

  94. Abram SE, Lightfoot RW. Treatment of long-standing causalgia with prazosin. Reg Anesth. 1981. 6:79-81.

  95. Ghostine SY, Comair YG, Turner DM, et al. Phenoxybenzamine in the treatment of causalgia. Report of 40 cases. J Neurosurg. 1984. 60:1263-1268.

  96. Stevens DS, Robins VF, Price HM. Treatment of sympathetically maintained pain with terazosin. Reg Anesth. 1993 Sep-Oct. 18(5):318-21. [Medline].

  97. Davis KD, Treede RD, Raja SN, Meyer RA, Campbell JN. Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain. 1991 Dec. 47(3):309-17. [Medline].

  98. Ziegler D, Lynch SA, Muir J, et al. Transdermal clondine versus placebo in painful diabetic neuropathy. Pain. 1992. 48:403-8.

  99. Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design. Pain. 1995 Mar. 60(3):267-74. [Medline].

  100. Devers A, Galer BS. Open-label trials of topical clonidine gel for the treatment of postherpetic neuralgia and complex regional pain syndrome. Presented at the American Pain Society,. November 1998.

  101. Cepeda MS, Lau J, Carr DB. Defining the therapeutic role of local anesthetic sympathetic blockade in complex regional pain syndrome: a narrative and systematic review. Clin J Pain. 2002 Jul-Aug. 18(4):216-33. [Medline].

  102. Schott GD. Interrupting the sympathetic outflow in causalgia and reflex sympathetic dystrophy. BMJ. 1998 Mar 14. 316(7134):792-3. [Medline].

  103. Price DD, Long S, Wilsey B, Rafii A. Analysis of peak magnitude and duration of analgesia produced by local anesthetics injected into sympathetic ganglia of complex regional pain syndrome patients. Clin J Pain. 1998 Sep. 14(3):216-26. [Medline].

  104. Cepeda MS, Carr DB, Lau J. Local anesthetic sympathetic blockade for complex regional pain syndrome, Cochrane Database Syst Rev. 2005. 4:CD004598.

  105. Hogan QH, Abram SE. Neural blockade for diagnosis and prognosis. A review. Anesthesiology. 1997 Jan. 86(1):216-41. [Medline].

  106. Wulf H, Gleim M, Schele HA. Plasma concentrations of bupivacaine after lumbar sympathetic block. Anesth Analg. 1994 Nov. 79(5):918-20. [Medline].

  107. Backonja M, Gombar K. Serum lidocaine levels following stellate ganglion sympathetic blocks and intravenous lidocaine injection. J Pain Sympton Manage. 1992. 7:2-3.

  108. Dellemijn PJI, Fields HL, Allen RR, et al. The interpretation of pain relief and sensory changes following sympathetic block. Brain. 1994. 17:1475-1487.

  109. Furst CI. The biochemistry of guanethidine. Adv Drug Res. 1967. 4:133-161.

  110. Bonelli S, Conoscente F, Movilia PG, Restelli L, Francucci B, Grossi E. Regional intravenous guanethidine vs. stellate ganglion block in reflex sympathetic dystrophies: a randomized trial. Pain. 1983 Jul. 16(3):297-307. [Medline].

  111. Rocco AG, Kaul AF, Reisman RM, Gallo JP, Lief PA. A comparison of regional intravenous guanethidine and reserpine in reflex sympathetic dystrophy. A controlled, randomized, double-blind crossover study. Clin J Pain. 1989 Sep. 5(3):205-9. [Medline].

  112. Blanchard J, Ramamurthy S, Walsh N, Hoffman J, Schoenfeld L. Intravenous regional sympatholysis: a double-blind comparison of guanethidine, reserpine, and normal saline. J Pain Symptom Manage. 1990 Dec. 5(6):357-61. [Medline].

  113. Field J, Atkins RM. Effect of guanethidine on the natural history of post-traumatic algodystrophy. Ann Rheum Dis. 1993 Jun. 52(6):467-9. [Medline].

  114. Geertzen JHB, deBruijn H, deBruijn-Kofman AT, et al. Reflex sympathetic dystrophy: early treatment and psychhological aspects. Arch Phys Rehabil. 1994. 75:442-446.

  115. Jadad AR, Carroll D, Glynn CJ, et al. Intravenous regional sympathetic blockade for pain relief in reflex sympathetic dystrphy: a systemic review and a randomized double-blind crossover study. J Pain Symptom Manage. 1995. 10:13-20.

  116. Ramamurthy S, Hoffman J, Group GS. Intravenous regional guanethidine in the treatment of reflex sympathetic dystrophy/causalgia: a randomized, double-blind study. Anesth Analg. 1995. 81:718-723.

  117. Hord AH, Rooks MD, Stephens BO, Rogers HG, Fleming LL. Intravenous regional bretylium and lidocaine for treatment of reflex sympathetic dystrophy: a randomized, double-blind study. Anesth Analg. 1992 Jun. 74(6):818-21. [Medline].

  118. Kettler RE, Abram SE. Intravenous regional droperidol in the management of reflex sympathetic dystrophy: a double-blind, placebo-controlled, crossover study. Anesthesiology. 1988 Dec. 69(6):933-6. [Medline].

  119. Hanna HM, Peat SJ. Ketanserin in reflex sympathetic dystrophy. A double-blind, placebo controlled, cross-over trial. Pain. 1989. 38:145-150.

  120. Glynn CJ, Stannard C, Collins PA, Casale R. The role of peripheral sudomotor blockade in the treatment of patients with sympathetically maintained pain. Pain. 1993 Apr. 53(1):39-42. [Medline].

  121. Torebjork HE, Hallin RG. Perceptual changes accompanying controlled preferential blocking of A and C fibre responses in intact human skin nerves. Exp Brain Res. 1973. 16:321-332.

  122. Ramirez JM, French AS. Phentolamine selectively affects the fast sodium component of sensory adaptation in an insect mechanoreceptor. J Neurobiol. 1990 Sep. 21(6):893-9. [Medline].

  123. Verdugo R, Ochoa JL. Sympathetically maintained pain. I. Phentolamine block questions the concept. Neurology. 1994. 44:1003-1010.

  124. Galer BS. Preliminary report: peak pain relief is delayed and duration of relief is extended following intravenous phentolamine infusion. Reg Anesth. 1995. 20:444-447.

  125. Raja SN, Turnquist JL, Meleka SM, et al. Monitoring adequacy of adrenergic blockade following systemic phentolamine administration. Pain. 1996. 64:197-204.

  126. Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain. 1994 Jan. 56(1):51-7. [Medline].

  127. Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J Pain Symptom Manage. 2000 Jan. 19(1 Suppl):S21-5. [Medline].

  128. Eide K, Stubhaug A, Oye I, Breivik H. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain. 1995 May. 61(2):221-8. [Medline].

  129. Admad M, Ackerman WE, Minur MA, Saleem M. NMDA Receptor Antagonists. Recent Advances in Chronic Pain. The Pain Clinic. 2001. 25-31.

  130. Pockett S. Spinal cord synaptic plasticity and chronic pain. Anesth Analg. 1995 Jan. 80(1):173-9. [Medline].

  131. Carpenter KJ, Dickenson AH. NMDA receptors and pain--hopes for novel analgesics. Reg Anesth Pain Med. 1999 Nov-Dec. 24(6):506-8. [Medline].

  132. Sunder RA, Toshniwal G, Dureja G. Ketamine as an adjuvant in sympathetic blocks for management of central sensitization following peripheral nerve injury. J Brachial Plex Peripher Nerve Inj. 2008 Oct 25. 3:22. [Medline]. [Full Text].

  133. Correll GE, Maleki J, Gracely EJ, Muir JJ, Harbut RE. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med. 2004 Sep. 5(3):263-75. [Medline].

  134. Kiefer RT, Rohr P, Ploppa A, Dieterich HJ, Grothusen J, Koffler S, et al. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study. Pain Med. 2008 Nov. 9(8):1173-201. [Medline].

  135. Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain. 2009 Oct. 145(3):304-11. [Medline].

  136. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain. 2009 Dec 15. 147(1-3):107-15. [Medline].

  137. Goebel A, Baranowski A, Maurer K, Ghiai A, McCabe C, Ambler G. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. Ann Intern Med. 2010 Feb 2. 152(3):152-8. [Medline].

  138. Collins S, Zuurmond WW, de Lange JJ, van Hilten BJ, Perez RS. Intravenous magnesium for complex regional pain syndrome type 1 (CRPS 1) patients: a pilot study. Pain Med. 2009 Jul-Aug. 10(5):930-40. [Medline].

  139. Fischer SG, Collins S, Boogaard S, Loer SA, Zuurmond WW, Perez RS. Intravenous magnesium for chronic complex regional pain syndrome type 1 (CRPS-1). Pain Med. 2013 Sep. 14(9):1388-99. [Medline].

  140. Groeneweg G, Huygen FJ, Niehof SP, Wesseldijk F, Bussmann JB, Schasfoort FC, et al. Effect of tadalafil on blood flow, pain, and function in chronic cold complex regional pain syndrome: a randomized controlled trial. BMC Musculoskelet Disord. 2008 Oct 20. 9:143. [Medline]. [Full Text].

  141. Birklein F, Sommer C. Intravenous immunoglobulin to fight complex regional pain syndromes: hopes and doubts. Ann Intern Med. 2010 Feb 2. 152(3):188-9. [Medline].

  142. Rauck RL, Eisenach JC, Jackson K, Young LD, Southern J. Epidural clonidine treatment for refractory reflex sympathetic dystrophy. Anesthesiology. 1993 Dec. 79(6):1163-9; discussion 27A. [Medline].

  143. AbuRahma AF, Robinson PA, Powell M, Bastug D, Boland JP. Sympathectomy for reflex sympathetic dystrophy: factors affecting outcome. Ann Vasc Surg. 1994 Jul. 8(4):372-9. [Medline].

  144. Bandyk DF, Johnson BL, Kirkpatrick AF et al. Surgical sympathectomy for reflex sympathetic dystrophy syndromes. J Vasc Surg. 2002. 35:269-77.

  145. Schwartzman RJ, Liu JE, Smullens SN, Hyslop T, Tahmoush AJ. Long-term outcome following sympathectomy for complex regional pain syndrome type 1 (RSD). J Neurol Sci. 1997 Sep 10. 150(2):149-52. [Medline].

  146. Singh B, Moodley J, Shaik AS, Robbs JV. Sympathectomy for complex regional pain syndrome. J Vasc Surg. 2003 Mar. 37(3):508-11. [Medline].

  147. Kemler MA, Barendse GA, van Kleef M, de Vet HC, Rijks CP, Furnee CA. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. N Engl J Med. 2000 Aug 31. 343(9):618-24. [Medline].

  148. Kemler MA, Furnée CA. Economic evaluation of spinal cord stimulation for chronic reflex sympathetic dystrophy. Neurology. 2002 Oct 22. 59(8):1203-9. [Medline].

  149. Calvillo O, Racz G, Didie J, Smith K. Neuroaugmentation in the treatment of complex regional pain syndrome of the upper extremity. Acta Orthop Belg. 1998 Mar. 64(1):57-63. [Medline].

  150. Stanton-Hicks M. Spinal cord stimulation for the management of complex regional pain syndromes. Neuromodulation. 1999. 193-201.

  151. Bennett D, Alo K, Oakley J, et al. Spinal cord stimulation for complex regional pain syndrome I (RSD): A retrospective multicenter experience from 1995-1998 of 101 patents. Neuromodulation. 1999. 3:202-10.

  152. Poree L, Krames E, Pope J, Deer TR, Levy R, Schultz L. Spinal cord stimulation as treatment for complex regional pain syndrome should be considered earlier than last resort therapy. Neuromodulation. 2013 Mar-Apr. 16(2):125-41. [Medline].

  153. Sherry DD, Wallace CA, Kelley C, Kidder M, Sapp L. Short- and long-term outcomes of children with complex regional pain syndrome type I treated with exercise therapy. Clin J Pain. 1999 Sep. 15(3):218-23. [Medline].

  154. Oerlemans HM, Oostendorp RA, de Boo T, Goris RJ. Evaluation of three methods to rate impairment in patients with complex regional pain syndrome I of one upper extremity. Clin Rehabil. 2000 Jun. 14(3):331-9. [Medline].

  155. Kemler MA, Rijks CP, de Vet HC. Which patients with chronic reflex sympathetic dystrophy are most likely to benefit from physical therapy? J Manipulative Physiol Ther. 2001. 24:272-8.

  156. Severens JL, Oerlemans HM, Weegels AJ, van 't Hof MA, Oostendorp RA, Goris RJ. Cost-effectiveness analysis of adjuvant physical or occupational therapy for patients with reflex sympathetic dystrophy. Arch Phys Med Rehabil. 1999 Sep. 80(9):1038-43. [Medline].

  157. Moseley CL. Is successful rehabilitation of complex regional pain syndrome due to sustained attention to the affected limb?. A randomised clinical trial, Pain. 2005. 114:54-61.

  158. Lee BH, Scharff L, Sethna NF, McCarthy CF, Scott-Sutherland J, Shea AM. Physical therapy and cognitive-behavioral treatment for complex regional pain syndromes. J Pediatr. 2002 Jul. 141(1):135-40. [Medline].

  159. de Jong JR, Vlaeyen JW, Onghena P, Cuypers C, den Hollander M, Ruijgrok J. Reduction of pain-related fear in complex regional pain syndrome type I: the application of graded exposure in vivo. Pain. 2005 Aug. 116(3):264-75. [Medline].

  160. Gierthmühlen J, Binder A, Baron R. Mechanism-based treatment in complex regional pain syndromes. Nat Rev Neurol. 2014 Sep. 10 (9):518-28. [Medline].

  161. Stanton-Hicks M, Baron R, Boas R, Gordh T, Harden N, Hendler N. Complex Regional Pain Syndromes: guidelines for therapy. Clin J Pain. 1998 Jun. 14(2):155-66. [Medline].

  162. Baron R, Binder A, Ulrich W et al. Complex regional pain syndrome. Reflex sympathetic dystrophy and causalgia. Nesvenarzt. 2002. 73:305-18,.(In German.).

  163. Evans JA. Reflex sympathetic dystrophy. Surg Gynecol Obstet. 1946. 82:36-44.

  164. Galer BS, Bruehl S, Harden RN. IASP diagnostic criteria for complex regional pain syndrome: a preliminary empirical validation study. International Association for the Study of Pain. Clin J Pain. 1998 Mar. 14(1):48-54. [Medline].

  165. Geertzen JH, Dijkstra PU, van Sonderen EL. Relationship between impairments, disability and handicap in reflex sympathetic dystrophy patients: a long term followup study. Clin Rehabil. 1998. 12:402-412.

  166. Kemler MA, van de Vusse AC, van den Berg-Loonen EM, Barendse GA, van Kleef M, Weber WE. HLA-DQ1 associated with reflex sympathetic dystrophy. Neurology. 1999 Oct 12. 53(6):1350-1. [Medline].

  167. Kurvers HA. Reflex sympathetic dystrophy: facts and hypotheses. Vasc Med. 1998. 3(3):207-14. [Medline].

  168. Mense S. Biochemical pathogenesis of myofascial pain. J Musculoskeletal Pain. 1996. 4:145-62.

  169. Mersky H, Bogduk N. Classification of chronic pain. Seattle: IASP Press. 1994.

  170. Ochoa JL. Truths, errors, and lies around "reflex sympathetic dystrophy" and "complex regional pain syndrome". J Neurol. 1999 Oct. 246(10):875-9. [Medline].

  171. Oerlemans HM, Oostendorp RA, de Boo T, Goris RJ. Pain and reduced mobility in complex regional pain syndrome I: outcome of a prospective randomised controlled clinical trial of adjuvant physical therapy versus occupational therapy. Pain. 1999 Oct. 83(1):77-83. [Medline].

  172. Oerlemans HM, Oostendorp RA, de Boo T, Perez RS, Goris RJ. Signs and symptoms in complex regional pain syndrome type I/reflex sympathetic dystrophy: judgment of the physician versus objective measurement. Clin J Pain. 1999 Sep. 15(3):224-32. [Medline].

  173. Pappagallo M. Complex regional pain syndromes. Neurology Reviews. 2000. 25-29.

  174. Portenoy RK. Davis Company. Neuropathic Pain. Philadelphia: FA: Pain Management: Theory and Practice.; 1996. 83-125.

  175. Roberts WJ. A hypothesis on the physiological basis for causalgia and related pains. Pain. 1986 Mar. 24(3):297-311. [Medline].

  176. Schurmann M, Gradl G, Andress HJ, Furst H, Schildberg FW. Assessment of peripheral sympathetic nervous function for diagnosing early post-traumatic complex regional pain syndrome type I. Pain. 1999 Mar. 80(1-2):149-59. [Medline].

  177. Thimineur MA, Saberski L. Complex regional pain syndrome type I (RSD) or peripheral mononeuropathy? A discussion of three cases. Clin J Pain. 1996 Jun. 12(2):145-50. [Medline].

  178. van der Laan L, ter Laak HJ, Gabreels-Festen A, Gabreels F, Goris RJ. Complex regional pain syndrome type I (RSD): pathology of skeletal muscle and peripheral nerve. Neurology. 1998 Jul. 51(1):20-5. [Medline].

  179. Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet. 1993 Oct 23. 342(8878):1012-6. [Medline].

  180. Wasner G, Binder A, Kopper F, Baron R. No effect of sympathetic sudomotor activity on capsaicin-evoked ongoing pain and hyperalgesia. Pain. 2000 Feb. 84(2-3):331-8. [Medline].

  181. Zyluk A. The natural history of post-traumatic reflex sympathetic dystrophy. J Hand Surg Br. 1998 Feb. 23(1):20-3. [Medline].

CPRS: complex regional pain syndrome; SMP: sympathetically maintained pain.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.